[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10]

Stanislas Quesada; Pauline Vaflard

doi:10.1016/j.bulcan.2021.09.021

[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10]

Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.

[Article in French]

Authors

Stanislas Quesada¹, Pauline Vaflard²

Affiliations

¹ Institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires - Parc Euromédecine, 34298 Montpellier cedex 5, France. Electronic address: stanislas.quesada@gmail.com.
² Institut Curie, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France.

PMID: 34998526
DOI: 10.1016/j.bulcan.2021.09.021

No abstract available

Keywords: Adénocarcinome de l’œsophage; Carcinome épidermoïde de l’œsophage; Immunotherapy; Immunothérapie; Oesophageal adenocarcinoma; Pembrolizumab; Squamous cell carcinoma.

Publication types

Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / metabolism
Adenocarcinoma / pathology
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
B7-H1 Antigen / biosynthesis
Drug Approval
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / metabolism
Esophageal Neoplasms / pathology
Humans
Neoplasm Metastasis
Neoplasm Staging
Receptor, ErbB-2
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / metabolism
Stomach Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
pembrolizumab
ERBB2 protein, human
Receptor, ErbB-2